CSNpharm
Bavachalcone, a major bioactive compounds isolated from Psoralea corylifolia L., has been widely used as traditional Chinese medicine and is an antibiotic or anticancer agent.
More Information
Supplier Page
CSNpharm
Bavachalcone, a major bioactive compounds isolated from Psoralea corylifolia L., has been widely used as traditional Chinese medicine and is an antibiotic or anticancer agent.
More Information
Supplier Page
CSNpharm
Bavachin, a flavonoid phytoestrogen, can activate the estrogen receptors ERα (EC50 = 320 nM) and ERβ (EC50 = 680 nM).
More Information
Supplier Page
CSNpharm
Bavachin, a flavonoid phytoestrogen, can activate the estrogen receptors ERα (EC50 = 320 nM) and ERβ (EC50 = 680 nM).
More Information
Supplier Page
CSNpharm
Bavachin, a flavonoid phytoestrogen, can activate the estrogen receptors ERα (EC50 = 320 nM) and ERβ (EC50 = 680 nM).
More Information
Supplier Page
CSNpharm
Bavachin, a flavonoid phytoestrogen, can activate the estrogen receptors ERα (EC50 = 320 nM) and ERβ (EC50 = 680 nM).
More Information
Supplier Page
CSNpharm
Bavachinin is an agonist of PPAR with EC50s of 4.0 µM, 8.1 µM, and 0.74 µM for α,β/δ, and γ respectively. It is a natural flavanone with anti-angiogenic effect.
More Information
Supplier Page
CSNpharm
Bavachinin is an agonist of PPAR with EC50s of 4.0 µM, 8.1 µM, and 0.74 µM for α,β/δ, and γ respectively. It is a natural flavanone with anti-angiogenic effect.
More Information
Supplier Page
CSNpharm
Bavachinin is an agonist of PPAR with EC50s of 4.0 µM, 8.1 µM, and 0.74 µM for α,β/δ, and γ respectively. It is a natural flavanone with anti-angiogenic effect.
More Information
Supplier Page
CSNpharm
BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. It also inhibits components of the ubiquitin system through inactivating the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex).
More Information
Supplier Page
CSNpharm
BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. It also inhibits components of the ubiquitin system through inactivating the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex).
More Information
Supplier Page
CSNpharm
BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. It also inhibits components of the ubiquitin system through inactivating the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex).
More Information
Supplier Page
CSNpharm
BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. It also inhibits components of the ubiquitin system through inactivating the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex).
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
BAY 2402234 is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor. It potently inhibited proliferation of AML cell lines in the sub-nanomolar to low-nanomolar range in vitro and exhibited strong in vivo anti-tumor efficacy in monotherapy in several subcutaneous and disseminated AML xenografts as well as AML patient-derived xenograft (PDX) models.
More Information
Supplier Page
CSNpharm
BAY 2402234 is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor. It potently inhibited proliferation of AML cell lines in the sub-nanomolar to low-nanomolar range in vitro and exhibited strong in vivo anti-tumor efficacy in monotherapy in several subcutaneous and disseminated AML xenografts as well as AML patient-derived xenograft (PDX) models.
More Information
Supplier Page
CSNpharm
BAY 2402234 is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor. It potently inhibited proliferation of AML cell lines in the sub-nanomolar to low-nanomolar range in vitro and exhibited strong in vivo anti-tumor efficacy in monotherapy in several subcutaneous and disseminated AML xenografts as well as AML patient-derived xenograft (PDX) models.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.
More Information
Supplier Page
CSNpharm
BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.
More Information
Supplier Page
CSNpharm
BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.
More Information
Supplier Page
CSNpharm
BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.
More Information
Supplier Page
CSNpharm
BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.
More Information
Supplier Page
CSNpharm
BAY 57-1293 represents a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex.
More Information
Supplier Page
CSNpharm
BAY 57-1293 represents a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex.
More Information
Supplier Page
CSNpharm
BAY 57-1293 represents a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex.
More Information
Supplier Page
CSNpharm
BAY 57-1293 represents a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex.
More Information
Supplier Page
CSNpharm
BAY 57-1293 represents a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
